Lifesci Capital Issues Optimistic Estimate for iBio Earnings

iBio, Inc. (NASDAQ:IBIO) – Research analysts at Lifesci Capital boosted their Q4 2026 EPS estimates for shares of iBio in a research report issued on Wednesday, May 13th. Lifesci Capital analyst P. Dolezal now expects that the company will earn ($0.06) per share for the quarter, up from their previous forecast of ($0.07). The consensus estimate for iBio’s current full-year earnings is ($0.32) per share. Lifesci Capital also issued estimates for iBio’s Q1 2027 earnings at ($0.06) EPS and Q2 2027 earnings at ($0.06) EPS.

A number of other equities analysts also recently commented on the stock. JonesTrading started coverage on shares of iBio in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iBio in a research report on Friday, March 27th. Chardan Capital reiterated a “buy” rating and issued a $5.00 price target on shares of iBio in a report on Thursday, April 9th. Finally, Wall Street Zen raised iBio from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Three equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, iBio presently has a consensus rating of “Buy” and an average price target of $4.75.

iBio Stock Performance

NASDAQ IBIO opened at $1.56 on Friday. The firm’s 50 day moving average price is $2.03 and its 200-day moving average price is $1.96. iBio has a 52-week low of $0.56 and a 52-week high of $3.82. The company has a market cap of $56.38 million, a PE ratio of -2.69 and a beta of 1.23.

iBio (NASDAQ:IBIO) last posted its earnings results on Tuesday, May 12th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01).

Institutional Investors Weigh In On iBio

Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new position in shares of iBio during the first quarter worth $224,000. Ameriprise Financial Inc. acquired a new stake in shares of iBio in the 3rd quarter worth $399,000. Boothbay Fund Management LLC boosted its position in shares of iBio by 10.9% in the 3rd quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company’s stock worth $146,000 after purchasing an additional 17,414 shares in the last quarter. Citadel Advisors LLC purchased a new position in iBio during the 3rd quarter worth $109,000. Finally, Susquehanna International Group LLP purchased a new position in iBio during the 3rd quarter worth $37,000. 7.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Felipe Duran acquired 24,835 shares of iBio stock in a transaction that occurred on Thursday, March 19th. The stock was purchased at an average price of $2.02 per share, for a total transaction of $50,166.70. Following the purchase, the chief financial officer directly owned 35,974 shares in the company, valued at $72,667.48. The trade was a 222.96% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 2.75% of the stock is currently owned by insiders.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.